Monday, 27 March 2017

Worldwide Ophthalmology Cataract Surgery Devices Market By Geography Products Analyzers 2016 - 2024

Cataract surgery is a procedure that removes clouding of the natural lens from the eye, an intraocular lens is implanted at the same time during the procedure. A person can be diagnosed with cataract by birth, or due to chemical or physical injury. The ophthalmology cataract surgery devices are used for the treatment of cataract, without causing any damage to the cornea. Cataract surgery is a low-risk procedure with an excellent record of safety and success. 

According to WHO, cataract is responsible for 51% of world blindness, which represents about 20 million people in 2010. There are three types of cataracts, such as nuclear cataracts, cortical cataracts and subcapsular cataracts. Cataract is one of the most common ocular disorders worldwide and is highly prevalent in the developed countries with rise in geriatric population. For example, as per the data enlisted National Institutes of Health (NIH), cataract is one of the leading causes for blindness worldwide and around 22 million Americans suffer from cataract and it has also stated that around 50% of the population will acquire cataract by the age of 80 years. These alarming statistics about cataract further provoke continuous technological advances to increase patient outcomes. Factors such as lack of health care insurance, lack of general awareness among people about eye disorders and poor primary health care infrastructure act as a barrier for ophthalmology cataract surgery devices market.


The cataract surgery devices market has been segmented by product type, by end-users and by geography. In terms of product type cataract surgery devices market is classified into intraocular lens (IOL), Ophthalmic Viscoelastic Device (OVD), Phacoemulsification Equipment and Femtosecond laser Equipment. Phacoemulsification is the most preferred cataract surgery device worldwide, whereas in developing countries such as China and India manual and sutureless Small-Incision Cataract Surgery (SICS) is preferred because of the lower costs of the procedure.

The adoption of foldable IOLs and advanced IOLs in emerging countries such as China and India is at a growing stage, due to factors such as reduced access to health care resources, and difference in income levels between urban and rural areas. The use of femtosecond lasers has ensured high efficiency along without any collateral tissue damages. The use of these lasers along with computer-controlled optical delivery systems has led to precise incisions without any damage to the surrounding tissues. By End-users, the market is further segmented as Hospitals, Clinics, and Ophthalmology centers.

Geographically, the global ophthalmology cataract surgery devices market is segmented as North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America dominated the ophthalmology cataract surgery devices market due to large geriatric population. According to Prevent blindness American, 17% of the U.S. population aged 40 years and older are affected by cataract, indicating that 24.4 million Americans are diagnosed with cataract. According to Novartis healthcare in 2015 nearly 4 million cataract surgeries were performed in the United States each year. Market saturation and slowing economy pose as barrier to the U.S. ophthalmology cataract surgery devices market's growth. However, Asia Pacific market is expected to grow at a lucrative growth rate owing to factors such as growing population, economic development in countries such as India and China support the market growth.

The major players operating in the global ophthalmology cataract surgery devices market include Carl Zeiss Meditech AG (Germany), Abbott Laboratories (U.S.), Alcon, Inc., Allergan, Inc. (U.S.), Bausch & Lomb, Inc. (U.S.), Essilor International S.A. (France), opcon Corporation (Japan), NIDEK Co., Ltd. (Japan), STAAR Surgical Company (U.S.) among other significant players worldwide.

The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape. 

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14126

About Us    

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Worldwide Urothelial Carcinoma Treatment Market Trends & Industry Forecast by 2016 - 2024

Urothelial carcinoma is a malignant neoplasm resulting from transitional epithelium, occurring mainly in the urinary bladder, renal pelves or ureters; frequently papillary. These carcinomas are classified according to the degree of anaplasia. Urothelial cell carcinoma (UCC) is a type of cancer that normally occurs in the urinary system: urinary bladder, kidney and accessory organs. It is the most common type of bladder, ureter, urethra, and urachus cancer. Urothelial cell carcinoma is also known as transitional cell carcinoma. Bladder transitional cell carcinoma (TCC) is the most common tumor of the entire urinary system and TCC is the most common primary neoplasm of the urinary bladder. Cancer of the ureter may not have symptoms in the early stages of the disease. However, symptoms may appear as the cancer grows. These include: persistent back pain, blood in the urine, painful or frequent urination, fatigue unexplained weight loss. These symptoms are associated with malignant cancer of the ureter and other health conditions. 

The treatment of Urothelial carcinoma involves surgery, chemotherapy and radiotherapy. The tests to diagnose Urothelial carcinoma includes Urine tests, Ureteroscopy, Intravenous pyelogram (IVP), Retrograde pyelography, CT scan, MRI scan and Chest X-ray. While the treatment with surgery include open surgery, laparoscopic surgery and percutaneous endoscopic surgery. Chemotherapy treatment usually involves the treatment with a combination of drugs. The combinations includes: gemcitabine and cisplatin, gemcitabine and carboplatin as well as methotrexate, vinblastine, doxorubicin and cisplatin. Radiotherapy is not frequently used for transitional cell carcinoma of the kidney or ureter. Patient may have radiotherapy to the area of the ureter or kidney if patients are not fit enough to have an operation or cancer has spread into surrounding tissue.


The Urothelial carcinoma market has been segmented by type of drugs, by end-user and by geography. The type of drugs sub-segmented as targeted and chemotherapy. The drugs like Levatinib, Atezolizumab, Nivelumab, Enzalutamide, Abiraterone acetate, Cabazitaxel, sipuleucel-T, everolimus, bevacizumab and pazopanib are used in treatment of Urothelial carcinoma. The end-users for the Urothelial carcinoma market include Hospitals, Specialty Clinics, Cancer Research Institutes and Ambulatory Surgical Centers.

Belgium holds the top rank in incidences of bladder cancer, which is followed by Lebanon and Malta. Bladder cancer cases occur in more developed countries, notably around 59%. The regions like Northern America and Europe having highest incidence of bladder cancer; and Asia, Latin America and the Caribbean having the lowest incidence. Transitional cell cancer develops in the part of the kidney called the renal pelvis. Transitional cell cancers are rare and only about 7 out of 100 kidney cancers (7%) diagnosed in the UK. The most common type of kidney cancer is renal cell cancer. Transitional cell cancer of the ureter is even more infrequent than transitional cell cancer of the kidney. TCC of the kidney is 4 times more common than cancer of the ureter. The most common type of bladder cancer is transitional cell cancers of the bladder. According to the estimation of American Cancer Society for bladder cancer, in 2016 there would be about 76,960 new cases of bladder cancer, and about 16,390 deaths from bladder cancer alone in the United States. In recent years the rates of cancer deaths and new bladder cancers have been dropping slightly in women. Incidence rates have been decreasing and death rates have been stable in men. About 5% of all newly diagnosed cancers in the US are Bladder cancers. It is the fourth most frequent cancer in men, but it is not common in women.

The major players operating in Urothelial carcinoma market include Genentech, GlaxoSmithKline, Genentech, Novartis, Dendreon, Sanofi Aventis, Bristol-Myers Squibb and Eisai are among other significant players worldwide.

The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape.  

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14060

About Us    

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Worldwide Traveler’s Diarrhea Market Analysis by Segments, Size and Forecast 2016 - 2024

Traveler’s Diarrhea Market: Overview

Traveler’s diarrhea refers to intestinal and stomach infection and occurs due to unsanitary conditions during handling of food. This disorder is characterized by frequent abdominal cramps resulting in loose stools and is usually caused by consumption of contaminated water or food. Travelling from one place to another where the sanitary conditions, social conditions, climate and other factors are different and hence presents high risk of developing traveler’s diarrhea. 

This is one of the most common condition affecting travelers every year, for example according to data enumerated by Centers for Disease Control and Prevention (CDC), around 20% to 50% an estimated 10 million of the international traveler’s develop traveler’s diarrhea every year. This disorder occurs during the travel period or post return and also in some cases one can experience multiple episodes of diarrhea during one trip. Developing countries of Latin America, Middle East, Asia and Africa represent the areas for highest risk of contracting traveler’s diarrhea. Immunosuppressed individuals, young adults and individuals with inflammatory bowel disorders and diabetic patients constitute the highly susceptible patient population for contracting traveler’s diarrhea.


Intensity of infection varies depending on the type of eating establishment. For instance, there is low risk of infection if the food is consumed in private homes and poses high risk of infection in the food from the street vendors. Nausea, vomiting, fever, frequent defecate and abdominal cramps are some of the common symptoms of traveler’s diarrhea. Most of the cases are benign and resolve quickly but sometimes sign and symptoms persist for several days and can be more severe in cases where it is caused by other organisms other than common bacteria. In these cases, prescription medicines are recommended for the treatment. Enterotoxigenic Escherichia coli is the most common causative agent of traveler’s diarrhea. Travelers can minimize the risk of developing traveler’s diarrhea by adopting several preventive measures such as use of bottled drinking water, avoiding consumption of raw or uncooked seafood and meat and raw fruits.

Consulting a doctor than self medication is preferred for the treatment of traveler’s diarrhea and especially relevant to pregnant women and children. There are several medications prescribed for the treatment of diarrhea. For example, Pepto-Bismol tablet shortens the duration of illness and decreases diarrhea. This drug is not advised to take for more than three weeks at a time as it results in certain side effects such as temporary blackening of stools and tongue, constipation, nausea and others. Also, the consumption of this is not recommended for the patients who have aspirin allergy, gout, renal insufficiency and who are already taking anticoagulants. Other treatment options are replacement of fluids and salts achieved by the intake of oral rehydration solutions such as oral rehydration salts (ORS).

Traveler’s Diarrhea Market: Segmentation

The market for traveler’s diarrhea can be analyzed by the various medications available for the treatment and the geographical landscape. Antimicrobial therapy is the most preferred one and fluoroquinolones are the most preferred. The geographical landscape elucidates the analysis of the market by four major geographies namely North America, Asia-Pacific, Europe and Rest of the World. In addition, factors such as side effects of the drugs, introduction of alternate therapies, and increased focus on preventive care would impact the market growth.

Furthermore, regulatory policies, marketing approvals for drugs and safety concerns would further influence the market growth. The major factors favoring the market growth are increasing cases of traveler’s diarrhea and growing tourism across the globe. On the other hand, factors such as side effects of the drugs and lack of accessibility to appropriate treatment might encumber the market growth.

Bayer AG, Johnson & Johnson, Merck & Co., Inc. and Novartis AG are some of the companies operating in this market.

The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape. 

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13433

About Us    

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Worldwide Selective Serotonin Reuptake Inhibitors Market by Type & Application 2016 - 2024

Selective Serotonin Reuptake Inhibitors Market: Overview

Selective serotonin reuptake inhibitors (SSRIs) elevate the extracellular level of neurotransmitters known as serotonin by inhibiting its uptake in presynaptic cells. Therefore, selective serotonin reuptake inhibitors are widely used as medication for the treatment of severe or persistent depression. In addition, selective serotonin reuptake inhibitors are also used in combination with therapies such as cognitive behavioral therapy (CBT). 

Furthermore, selective serotonin reuptake inhibitors are also used for mental conditions such as panic disorders, obsessive compulsive disorder (OCD), post-traumatic stress disorder (PTSD), severe phobias, including social phobia and agoraphobia, and generalized anxiety disorder (GAD). In addition, selective serotonin reuptake inhibitors are also used for the treatment of premenstrual syndrome, premature ejaculation, irritable bowel syndrome and fibromyalgia. Side effects of selective serotonin reuptake inhibitors include, low sex drive, dizziness, sickness, anxiety, erectile dysfunction in male population and blurred vision. 


Selective Serotonin Reuptake Inhibitors Market: Growth Enablers

According to the World Health Organization (WHO), depression is the fourth leading cause of deaths and by 2020; it is expected to be the second leading cause of deaths worldwide. According to the National Institute of Mental Health (NIHM), part of National Institute of Health (NIH) of the U.S., in 2012, around 16 million adults above 18 years of age had at least one major depressive episode in the past year in the U.S. Risk of depression is twice in women population.

According to the Depression and Bipolar Support Alliance, the lifetime prevalence for female population is 20% to 26%. While life time prevalence of depression for male population is 8% to 12%. According to the article published by the British Psychology Society in June 2013, finding from the Office for National Statistics (ONS) states that approximately one fifth of the overall adult population experience depression. Thus, perpetually rising prevalence depression worldwide is the major factor driving the growth of the global selective serotonin reuptake inhibitors (SSRIs) market.

Selective Serotonin Reuptake Inhibitors Market: Region-wise Insight

Geographically, the selective serotonin reuptake inhibitors market is segmented into North America, Europe, Asia Pacific and Rest of the World (RoW). Presently, Europe and North America are dominating the global selective serotonin reuptake inhibitors (SSRIs) market. Factors such as, divorce, unemployment, work pressure, and higher life expectations are resulting in higher rate of depression cases.

Furthermore, availability of advanced healthcare facilities and higher healthcare spending are driving the growth of selective serotonin reuptake inhibitors market in Europe and North America. Asia Pacific is a lucrative market for selective serotonin reuptake inhibitors (SSRIs). Factors such as rapidly growing prevalence of depression and mental conditions, rising awareness about depression and related treatments available and rising healthcare expenditure are expected to drive the selective serotonin reuptake inhibitors market in Asia Pacific region.

Though, prevalence rate of depression is high in Rest of the World (RoW), lack of awareness about related treatment is limiting the growth of the selective serotonin reuptake inhibitors market in this region. Brazil and Argentina are expected to show faster growth rate than other countries in Rest of the World owing to availability of well defined regulatory framework and developed healthcare infrastructure. African countries will experience slower growth rate in the forecast period due to poorly developed healthcare infrastructure coupled with lack of availability of regulatory framework.
Some of the commercially available brands of SSRI include Fluvoxamine (Luvox), Citalopram (Celexa), Fluoxetine (Prozac), Paroxetine (Paxil), and Sertraline (Zoloft).

The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape. 

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13343

About Us    

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Worldwide Antiviral Drugs Market By Analysis of Major Industry Segments 2016 - 2024

Global Antiviral Drugs Market: Overview 

In past 30 years, significant progress is seen in antiviral drugs market, mainly in case of the drugs that target the entry and escaping mechanisms of viruses, with an aim of improving the quality of patient’s life by introducing broad spectrum of combination therapy drugs. Viruses rely on host’s machinery for replication as well as metabolic activities, thus antiviral agents target these mechanisms by several inhibitor classes such as Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Fusion Inhibitors (FIs), Entry Inhibitors - CCR5 co-receptor antagonist, Protease Inhibitors (PIs), HIV Integrase strand transfer inhibitors, among others. 
Demand for new and improved targeted therapies for viral diseases continues to rise, primarily due to invention of broad spectrum antiviral drugs. Introduction of combinational drug therapies with improved pharmacokinetic and pharmacodynamics properties, and focus on emerging regions for market penetration by creating awareness along with availability of affordable drugs are major opportunities for the global antiviral drugs market. 

The market overview section of the report comprises qualitative analysis of the overall antiviral drugs market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s five force analysis and market attractiveness analysis. In addition, such as market opportunity analysis for the disease indications, product type, and distribution channels, and key industry developments has also been provided. Key industry developments include the major events occurred in past decade and are expected to occur during the forecast period which are likely to affect the market dynamics. The prevalence HIV infection and HCV infection has also been provided, along with the FDA approvals and patent expiries of major drugs by each drug class. The pipeline analysis of major market players has been given in the market overview section. 


Global Antiviral Drugs Market: Segmentation 

The global antiviral drugs market has been segmented on the basis of disease indication, product type, and distribution channels. On the basis of disease indication, the global antiviral drugs market is categorized as hepatitis virus infection, HIV infection, Respiratory virus infection, and others. In terms of product type, the global antiviral drugs market is divided into branded drugs, and generic drugs. Furthermore, on the basis of distribution channels, the global antiviral drugs market has been classified as hospital pharmacy store, retail pharmacy store, and online pharmacy.

The market for these disease indication, product type, and distribution channels has been extensively analyzed on the basis of factors such as drug usage pattern, sales revenue, geographic presence and technological developments. The market size and forecast in terms of revenue (USD million) for each of these segments have been provided for the period 2014 to 2024, considering 2015 as the base year. The report also provides the compounded annual growth rate (CAGR) for each segment for the forecast period 2016 to 2024. 

Geographically, the antiviral drugs market has been classified into five segments, namely, North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The market size and forecast for each region has been provided for the period 2014 to 2024, in terms of disease indication, product type, and distribution channels, along with the CAGR (%) for the forecast period 2016 to 2024. 

Global Antiviral Drugs Market: Competitive Analysis 

The report also provides a section on the competitive landscape, wherein the market share analysis of leading players in the global antiviral drugs market, in terms of percentage share in 2016 (estimated) has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market share. 

The report concludes with the profiles of major players in the global antiviral drugs market such as AbbVie, Inc., Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Mylan N.V., GlaxoSmithKline plc. Johnson & Johnson, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., among others. The major market players are evaluated on various parameters such as company overview, financial overview, product portfolio, business strategies and recent developments. 

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=21083

About Us    

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.